Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management

Christopher Luzzio, MD; Kerstin Hellwig, MD


June 30, 2022

Relapsing-remitting multiple sclerosis (RRMS) accounts for approximately 85% of multiple sclerosis (MS) cases. It is characterized by recurrent episodes of various neurologic deficits that resolve over a short period with variable to no obvious residual deficit. Several pharmaceutical agents for MS have been approved by the U.S. Food and Drug Administration (FDA) to treat patients with clinically definite RRMS. Though none of these disease-modifying therapies (DMTs) cure the disease, all have shown efficacy in reducing clinical relapses and suppressing development of new lesions on MRI. Some slow the rate of disability progression.

How familiar are you with the management of RRMS? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.